Skip to main content
HairCited

螺内酯(Spironolactone) 用于 女性型脱发

A

基于19项研究(2项荟萃分析、4项RCT),共5,743名参与者。16/19项研究显示积极效果。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dspironolactone\u0026condition\u003Dfemale\u002Dpattern\u002Dhair\u002Dloss'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

结论

Spironolactone is strongly supported by research as an effective option that may help women with female pattern hair loss, with both oral and topical formulations showing benefits in clinical trials.

  • 84% of studies show positive effects, including 4 RCTs focused on women
  • Both oral and topical formulations have demonstrated benefits
  • A dedicated meta-analysis confirms efficacy and safety in female pattern hair loss
  • Combination with minoxidil may offer enhanced results

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None 效果: None None

研究人群: women with androgenetic alopecia (female pattern hair loss)

Randomized Controlled Trial n=204 24 weeks Double-blind
Spironolactone versus Bicalutamide in female pattern hair loss: A randomised clinical trial.
Dose: Bicalutamide 50 mg/day; spironolactone 100 mg/day vs: Spironolactone 100 mg/day Outcome: Hair density and shaft diameter change at 24 … 效果: Frontal: +5.05 vs +3.13 hairs/cm2 (diff 1.92) P < 0.001 (frontal); P = 0.028

研究人群: Women 18-50 with Sinclair Grade II-V FPHL (India)

randomized controlled trial n=80 24 weeks Single-blind
Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment …
Dose: Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily vs: Placebo 效果: Both groups showed statistically significant improvement. Group A: 10 mild, 16 moderate, 2 excellent None
RCT n=48 24 weeks Double-blind
Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a …
Dose: Spironolactone 100 mg once daily vs: Placebo 效果: Terminal hair counts: 9.48 vs 5.32 hairs/cm2; hair diameter: 4.23 vs 2.96 μm; moderate-to-marked imp p=0.063 (terminal hair counts)
Randomized Controlled Trial n=240 520 weeks Open-label
Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of …
Dose: None vs: Laparoscopic Roux-en-Y gastric bypass (LRYGB) Outcome: Nutritional deficiency prevalence at 10 years 效果: Iron deficiency: LSG 14% vs LRYGB 41% p=0.017 (iron deficiency)

研究人群: Severely obese adults undergoing bariatric surgery

Review
Male and female pattern hair loss.
Dose: None vs: Placebo 效果: None None

Key Statistics

45

研究数量

6441

受试者

Positive

A

等级

Referenced Papers

Australian prescriber 2025 2 次引用
Journal of cosmetic … 2023 3 次引用
Journal of the … 2020 43 次引用
Clinical and experimental … 2020 20 次引用
International journal of … 2018 129 次引用
Australian journal of … 2018 8 次引用
The Cochrane database … 2016 18 次引用
The Medical clinics … 2015 66 次引用
Journal of the … 2015 50 次引用
Clinical obstetrics and … 2015 9 次引用
Current problems in … 2015 8 次引用
Der Hautarzt; Zeitschrift … 2013 19 次引用
International journal of … 2013
The Australasian journal … 2011 44 次引用
Skinmed 2010 33 次引用
Seminars in cutaneous … 2009 4 次引用
Duodecim; laaketieteellinen aikakauskirja 2006
Journal of the … 2005 247 次引用
The British journal … 2005 205 次引用
Journal of the … 2005 64 次引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

常用剂量

hairloss:
100-200 mg/day (prescription)

上限: 200 mg/day (hair loss indication)

研究中使用的剂量

剂量 持续时间 效果 N
None -- Neutral --
Bicalutamide 50 mg/day; spironolactone 100 mg/day 24 weeks Positive 204
Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily 24 weeks Positive 80
Spironolactone 100 mg once daily 24 weeks Positive 48
None 520 weeks Positive 240
None -- Positive --
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
4 g -- Neutral --

最佳服用时间: Once or twice daily with food; prescription required

Safety & Side Effects

已报告的副作用

  • Menstrual irregularities
  • Breast tenderness
  • Hyperkalemia (elevated potassium levels)
  • Dizziness and orthostatic hypotension
  • Frequent urination

已知相互作用

  • ACE inhibitors and ARBs (increased hyperkalemia risk)
  • Potassium supplements and potassium-sparing diuretics (dangerous hyperkalemia)
  • NSAIDs (may reduce diuretic effectiveness and increase kidney risk)
  • Digoxin (spironolactone may increase digoxin levels)

可耐受最高摄入量: 200 mg/day (hair loss indication)

在开始服用任何补充剂之前,请务必咨询您的医疗保健提供者。

Frequently Asked Questions

Does 螺内酯(Spironolactone) help with 女性型脱发?
Based on 45 studies with 6,441 participants, there is strong evidence from multiple clinical trials that 螺内酯(Spironolactone) may support 女性型脱发 management. Our evidence grade is A (Strong Evidence).
How much 螺内酯(Spironolactone) should I take for 女性型脱发?
Studies have used various dosages. A commonly studied range is 100-200 mg/day (prescription). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 螺内酯(Spironolactone)?
Reported side effects may include Menstrual irregularities, Breast tenderness, Hyperkalemia (elevated potassium levels), Dizziness and orthostatic hypotension. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 螺内酯(Spironolactone) and 女性型脱发?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 45 peer-reviewed studies with 6,441 total participants. The overall direction of effect is positive.

Related Evidence

FDA 免责声明: 这些声明未经美国食品药品监督管理局(FDA)评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析,不构成医疗建议。在开始任何补充剂方案之前,请务必咨询您的医疗保健提供者。